Gyre Therapeutics (GYRE) Times Interest Earned (2010 - 2024)
Gyre Therapeutics (GYRE) posted quarterly Times Interest Earned of -$11.08 for Q1 2026, down 409.65% year-over-year from $3.58 in Q1 2025, and down 2514.08% quarter-over-quarter from $0.46 in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Times Interest Earned (2010 - 2024) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Times Interest Earned for 15 consecutive years, with -$11.08 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 409.65% year-over-year to -$11.08; the TTM figure through Mar 2026 stood at -$0.17 (down 101.02% YoY), while the FY2025 annual figure was $0.13, up 52.73% from the prior year.
- Times Interest Earned retreated to -$11.08 in Q1 2026 per GYRE's latest filing, from $0.46 in the prior quarter.
- Across five years, Times Interest Earned topped out at $105.49 in Q3 2023 and bottomed at -$861.0 in Q3 2022.
- Historically, Times Interest Earned has averaged -$66.61 across 5 years, with a median of $2.22 in 2024.
- On a YoY basis, Times Interest Earned climbed as much as 636.23% in 2022 and fell as far as 8349.94% in 2022.
- Gyre Therapeutics' Times Interest Earned stood at $24.82 in 2022, then slumped by 1866.61% to -$438.43 in 2023, then jumped by 100.63% to $2.76 in 2024, then sank by 83.36% to $0.46 in 2025, then slumped by 2514.08% to -$11.08 in 2026.
- Business Quant data shows GYRE's Times Interest Earned at -$11.08 in Q1 2026, $0.46 in Q4 2025, and $5.72 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 25.62 |
| Mar 31, 2023 | 10.36 |
| Dec 31, 2020 | -265.37 |
| Sep 30, 2020 | -2,300.00 |
| Dec 31, 2019 | 411.38 |
| Dec 31, 2015 | -212.86 |
| Sep 30, 2015 | -2.70 |
| Jun 30, 2015 | -56.44 |
| Dec 31, 2014 | -599.33 |
| Sep 30, 2014 | -327.60 |
| Jun 30, 2014 | -368.33 |
| Mar 31, 2014 | -207.00 |
| Dec 31, 2013 | -1,330.80 |
| Sep 30, 2013 | -1,011.23 |
| Jun 30, 2013 | -892.00 |
| Mar 31, 2013 | -517.13 |
| Dec 31, 2012 | -903.33 |
| Sep 30, 2012 | -404.90 |
| Jun 30, 2012 | 647.00 |
| Mar 31, 2012 | 76.38 |